Excess Cancer Mortality in Six Dutch Pedigrees with the Familial Atypical Multiple Mole-Melanoma Syndrome from 1830 to 1994
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
An increased incidence of systemic cancers has been described in some reports of familial atypical multiple mole-melanoma kindreds. If the gene defect underlying the familial atypical multiple mole-melanoma syndrome is not only important for the development of melanoma of the skin, the impact of the defect on life expectancy may be much higher than previously thought. We investigated all-cause mortality from 1830 to the present and causes of death from 1941 to 1994 in proven, obligate, and potential CDKN2 mutation carriers to obtain an estimate of the impact of a hereditary defect of the CDKN2 gene on mortality. From 1830 to 1994 there were 65 deaths, although only 42 deaths were expected [standardized mortality ratio (SMR) 1.6, 95% confidence interval (CI) 1.2-2.0] and the SMR doubled with calendar time. Excess mortality was shown in most of the families, but was confined to ages 35-70 y (SMR 2.1, 95%CI 1.5-2.9). Excess mortality could be fully attributed to cancer mortality, especially to pancreatic carcinoma and melanoma of the skin. There appeared to be some heterogeneity among the families, especially due to the specific cancer pattern within a family. The impact of the defect of the CDKN2 gene is rising over calendar time, mainly because the mortality in the general population has been falling. Excess mortality was not only due to melanoma, but also to pancreatic carcinoma. Therefore, follow-up programs of affected family members should not be confined to a regular check of the atypical nevi.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818 · cited 1×
“The three known melanoma susceptibility loci are located on 1p36 (Bale et al, 1989), 12q13 (Zuo et al, 1996), and 9p21 (Kamb et al, 1994).”
Background
Cited by
Vasen, H. F. A., Gruis, N. A., Frants, R. R., van der Velden, P. A., Hille, E. T. M., & Bergman, W. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000915)87:6<809::aid-ijc8>3.0.co;2-u · Cited by 347
Self-citationVasen, H. F. A., Wasser, M., van Mil, A., Tollenaar, R. A., Konstantinovski, M., Gruis, N. A., Bergman, W., Hes, F. J., Hommes, D. W., Offerhaus, G. J. A., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.048 · Cited by 152
Self-citationRisk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers
Mukherjee, B., DeLancey, J. O., Raskin, L., Everett, J., Jeter, J., Begg, C. B., Orlow, I., Berwick, M., Armstrong, B. K., Kricker, A., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs221 · Cited by 42
Metadata
- Authors
- Hille, E. T. M., van Duijn, E., Gruis, N. A., Rosendaal, F. R., Bergman, W., & Vandenbroucke, J. P.
- Venue
- Journal of Investigative Dermatology
- Publisher
- Elsevier BV
- Published
- 1998-05
- Volume
- 110
- Issue
- 5
- Pages
- 788-792
- ISSN
- 0022-202X (ISSN-L)
- OpenAlex
- W2115216436
- Cited by
- 45
- References
- 1
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Excess Cancer Mortality in Six Dutch Pedigrees with the Familial Atypical Multiple Mole-Melanoma Syndrome from 1830 to 1994. https://app.cochat.ai/papers/10.1046/j.1523-1747.1998.00185.x
- The paper
- Hille, E. T. M., van Duijn, E., Gruis, N. A., Rosendaal, F. R., Bergman, W., & Vandenbroucke, J. P. (1998). Excess Cancer Mortality in Six Dutch Pedigrees with the Familial Atypical Multiple Mole-Melanoma Syndrome from 1830 to 1994. Journal of Investigative Dermatology. https://doi.org/10.1046/j.1523-1747.1998.00185.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.